Sorafenib Tosylate APIs, provided by Loncom Pharma, are integral in creating multi-kinase inhibitors for treating advanced liver, kidney, and thyroid cancers. These APIs disrupt cancer cell signaling and angiogenesis, offering a lifeline to patients with hard-to-treat tumors.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
